The owner of Cadbury said on Monday it's no longer pursuing a deal to acquire Hershey. The news sent shares of the iconic U.S. chocolate maker plunging 11% in after-hours trading.
Competition is coming in the EpiPen controversy -- from Mylan itself. The company that makes EpiPen surprised analysts on Monday by announcing plans to launch a generic version of the allergy treatment at a 50% discount.
On Friday Janet Yellen reiterated again that the government has to spend more during crises. Both Hillary Clinton and Donald Trump want to boost spending.
Investment bank UBS says Wall Street, energy and retail could be big winners if Donald Trump is the next president. But overall stocks and bonds would likely do better under Hillary Clinton.
St. Jude Medical called claims that its pacemakers are vulnerable to cyber attacks "absolutely untrue." Investors sound worried though, sending the company's stock dropping 8%.
One year after America was in shock over the massive price hike of Daraprim from $13.50 to $750 a pill. Now the drug costs $375. Doctors say it's 'immoral' and 'unethical.'